Efficacy and safety of bosentan therapy in pulmonary hypertension: Meta-analysis / 中国医师进修杂志

ABSTRACT

Objective To pool the data of studies about bosentan therapy in pulmonary hypertension (PAH) and evaluate the efficacy and safety of bosentan therapy. Methods A search was performed in PubMed (from 01/01/1968 to 01/05/2006), Embase (from 01/01/1980 to 01/05/2006) and China National Knowledge Infrastructure (CNKI) (from 01/ 01/ 1978 to 01/ 05/ 2006) to identify relevant articles. Randomized-Controlled Trials (RCT) about the efficacy and safety of bosentan therapy in PAH patients were included to evaluate the short-term and long-term efficacy and safety of bosentan therapy in a method of Meta-analysis. Results (1)Two RCT studies including 243 PAH patients were chosen to evaluate the short-term efficacy and safety of bosentan therapy. Compared with placebo treatment, bosentan therapy could improve exercise capacity of PAH patients① Distance covered in a 6-minute walk test increased 47.71 meters (95% CI26.09 to 69.33, P